Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to
E: A critical review of viral hepatitis. World J Gastroenterol. 2021 Apr;27(16):1691–
715.
Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis a comprehensive review. J Hepatol. 2017 Dec;67(6):1298–323.
Reshetnyak VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its
diagnosis. World J Gastroenterol. 2015 Jul;21(25):7683–708.
Sahebjam F, Vierling JM. Autoimmune hepatitis. Front Med. 2015 Jun;9(2):187–219.
Schonfeld EA, Brown RS. Genetic Causes of Liver Disease: When to Suspect a
Genetic Etiology, Initial Lab Testing, and the Basics of Management. Med Clin North
Am. 2019 Nov;103(6):991–1003.
6 Zhou W-C, Zhang Q-B, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol.
2014 Jun;20(23):7312–24.
Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283–
98.
Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA.
Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis
in the United States. Gastroenterology. 2011 Oct;141(4):1249–53.
Farrell GC, Wong VW-S, Chitturi S. NAFLD in Asia--as common and important as
62
in the West. Nat Rev Gastroenterol Hepatol. 2013 May;10(5):307–18.
10 Abul-Husn NS, Cheng X, Li AH, Xin Y, Schurmann C, Stevis P, et al. A ProteinTruncating HSD17B13 Variant and Protection from Chronic Liver Disease. N Engl J
Med. 2018 Mar;378(12):1096–106.
11 Eslam M, Mangia A, Berg T, Chan HLY, Irving WL, Dore GJ, et al. Diverse impacts
of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease
phenotypes. Hepatology. 2016 Jul;64(1):34–46.
12 Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to
uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):40–52.
13 Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjærg-Hansen A,
et al. Exome-wide association study identifies a TM6SF2 variant that confers
susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014 Apr;46(4):352–6.
14 Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic
variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat
Genet. 2008 Dec;40(12):1461–5.
15 Oniki K, Saruwatari J, Izuka T, Kajiwara A, Morita K, Sakata M, et al. Influence of
the PNPLA3 rs738409 Polymorphism on Non-Alcoholic Fatty Liver Disease and
Renal
Function
among
Normal
Weight
Subjects.
PLoS
ONE.
2015
Jul;10(7):e0132640.
16 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ.
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
63
Gastroenterology. 1999 Jun;116(6):1413–9.
17 Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al.
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and
ability to predict liver-related mortality. Hepatology. 2011 Jun;53(6):1874–82.
18 Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR.
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological
lesions. Am J Gastroenterol. 1999 Sep;94(9):2467–74.
19 Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.
Design and validation of a histological scoring system for nonalcoholic fatty liver
disease. Hepatology. 2005 Jun;41(6):1313–21.
20 Bedossa P, FLIP Pathology Consortium. Utility and appropriateness of the fatty liver
inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF)
score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology.
2014 Aug;60(2):565–75.
21 Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, et al. Clinical
validation of the FLIP algorithm and the SAF score in patients with non-alcoholic
fatty liver disease. J Hepatol. 2020 May;72(5):828–38.
22 Sumida Y, Yoneda M. Current and future pharmacological therapies for
NAFLD/NASH. J Gastroenterol. 2018 Mar;53(3):362–76.
23 Romero FA, Jones CT, Xu Y, Fenaux M, Halcomb RL. The Race to Bash NASH:
Emerging Targets and Drug Development in a Complex Liver Disease. J Med Chem.
64
2020 May;63(10):5031–73.
24 C Y Fan, J Pan, N Usuda, A V Yeldandi, M S Rao, J K Reddy. Steatohepatitis,
spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal
fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor
alpha natural ligand metabolism. The Journal of biological chemistry. 1998
Jun;273(25):15639-45.
25 Lindström P. The physiology of obese-hyperglycemic mice [ob/ob mice].
ScientificWorldJournal. 2007 May;7:666–85.
26 Okumura K, Ikejima K, Kon K, Abe W, Yamashina S, Enomoto N, et al. Exacerbation
of dietary steatohepatitis and fibrosis in obese, diabetic KK-A(y) mice. Hepatol Res.
2006 Nov;36(3):217–28.
27 Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL,
et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear
SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes
Dev. 1998 Oct;12(20):3182–94.
28 Trak-Smayra V, Paradis V, Massart J, Nasser S, Jebara V, Fromenty B. Pathology of
the liver in obese and diabetic ob/ob and db/db mice fed a standard or high-calorie
diet. Int J Exp Pathol. 2011 Dec;92(6):413–21.
29 Horai Y, Utsumi H, Ono Y, Kishimoto T, Ono Y, Fukunari A. Pathological
characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an
experimental non-alcoholic steatohepatitis model, induced by high-fat and high-
65
cholesterol diet. Int J Exp Pathl. 2016 Feb;97(1):75–85.
30 L L. Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis
& tissue repair. 2013 Jul 18;6(1):14.
31 Okishio S, Yamaguchi K, Ishiba H, Tochiki N, Yano K, Takahashi A, et al. PPARα
agonist and metformin co-treatment ameliorates NASH in mice induced by a cholinedeficient, amino acid-defined diet with 45% fat. Sci Rep. 2020 Nov;10(1):19578.
32 Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of
hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid
Res. 2008 May;49(5):1068–76.
33 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of
NAFLD development and therapeutic strategies. Nat Med. 2018 Jul;24(7):908–22.
34 Pais R, Maurel T. Natural History of NAFLD. J Clin Med. 2021 Mar 10;10(6):1161.
35 Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex
Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification
of Research Gaps. Hepatology. 2019;70(4):1457–69.
36 Sarkar MA, Suzuki A, Abdelmalek MF, Yates KP, Wilson LA, Bass NM, et al.
Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in
Premenopausal Women With NAFLD. Clinical Gastroenterology and Hepatology.
2021 Jun;19(6):1267-1274.e1.
37 DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for
66
Diagnosis and Treatment. Endocrinology. 2020 Oct 1;161(10):bqaa134.
38 Farruggio S, Cocomazzi G, Marotta P, Romito R, Surico D, Calamita G, et al.
Genistein and 17β-Estradiol Protect Hepatocytes from Fatty Degeneration by
Mechanisms Involving Mitochondria, Inflammasome and Kinases Activation | Cell
Physiol Biochem. Cellular Physiology & Biochemistry. 2020 Apr;54(3):401–16.
39 Nadal-Casellas A, Proenza AM, Lladó I, Gianotti M. Sex-dependent differences in rat
hepatic lipid accumulation and insulin sensitivity in response to diet-induced obesity.
Biochem Cell Biol. 2012 Apr;90(2):164–72.
40 Stöppeler S, Palmes D, Fehr M, Hölzen JP, Zibert A, Siaj R, et al. Gender and strainspecific differences in the development of steatosis in rats. Lab Anim. 2013
Jan;47(1):43–52.
41 Perry AC, Martin L. Race differences in obesity and its relationship to the sex
hormone milieu. Horm Mol Biol Clin Investig. 2014 Sep;19(3):151–61.
42 Shepard BD. Sex differences in diabetes and kidney disease: mechanisms and
consequences. Am J Physiol Renal Physiol. 2019 Aug;317(2):F456–62.
43 Masuyama T, Katsuda Y, Shinohara M. A Novel Model of Obesity-Related Diabetes:
Introgression of the Leprfa Allele of the Zucker Fatty Rat into Nonobese
Spontaneously Diabetic Torii (SDT) Rats. Experimental Animals. 2005;54(1):13–20.
44 Ishii Y, Motohashi Y, Muramatsu M, Katsuda Y, Miyajima K, Sasase T, et al. Female
spontaneously diabetic Torii fatty rats develop nonalcoholic steatohepatitis-like
hepatic lesions. World J Gastroenterol. 2015 Aug;21(30):9067–78.
67
45 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev
Gastroenterol Hepatol. 2017 Jan;14(1):32–42.
46 Fukui M, Senmaru T, Hasegawa G, Yamazaki M, Asano M, Kagami Y, et al. 17βEstradiol attenuates saturated fatty acid diet-induced liver injury in ovariectomized
mice by up-regulating hepatic senescence marker protein-30. Biochemical and
Biophysical Research Communications. 2011 Nov;415(2):252–7.
47 Kanaya N, Kubo M, Liu Z, Chu P, Wang C, Yate-Ching Yuan SC. Protective Effects
of White Button Mushroom (Agaricus bisporus) against Hepatic Steatosis in
Ovariectomized Mice as a Model of Postmenopausal Women. PLOS ONE. 2011
Oct;6(10):e26654.
48 Kamada Y, Matsumoto H, Tamura S, Fukushima J, Kiso S, Fukui K, et al.
Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic
steatohepatitis mouse model. Journal of Hepatology. 2007 Oct;47(4):556–64.
49 Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, et al. An improved
mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis.
International Journal of Experimental Pathology. 2013;94(2):93–103.
50 Ibrahim SH, Hirsova P, Malhi H, Gores GJ. Animal Models of Nonalcoholic
Steatohepatitis: Eat, Delete, and Inflame. Dig Dis Sci. 2016 May;61(5):1325–36.
51 Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon tetrachloride model in
mice. Lab Anim. 2015 Apr;49(1 Suppl):4–11.
52 Ishii Y, Ohta T, Sasase T, Morinaga H, Ueda N, Hata T, et al. Pathophysiological
68
analysis of female Spontaneously Diabetic Torii fatty rats. Exp Anim. 2010;59(1):73–
84.
53 Blasiole DA, Davis RA, Attie AD. The physiological and molecular regulation of
lipoprotein assembly and secretion. Mol Biosyst. 2007 Sep;3(9):608–19.
54 Resseguie M, Song J, Niculescu MD, Costa K-A da, Randall TA, Zeisel SH.
Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced
by estrogen in human and mouse primary hepatocytes. The FASEB Journal.
2007;21(10):2622–32.
55 Nakatsuka A, Matsuyama M, Yamaguchi S, Katayama A, Eguchi J, Murakami K, et
al. Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean
non-alcoholic steatohepatitis. Sci Rep. 2016 Feb;6:21721.
56 Barsalani R, Chapados NA, Lavoie J-M. Hepatic VLDL-TG production and MTP
gene expression are decreased in ovariectomized rats: effects of exercise training.
Horm Metab Res. 2010 Nov;42(12):860–7.
57 Hata T, Ohta T, Ishii Y, Sasase T, Yamaguchi T, Mera Y, et al. Elevated glucagon-like
peptide-1 on a high-fat diet feeding prevents the incidence of diabetes mellitus in
Spontaneously Diabetic Torii Leprfa rats. 2012 May;2(2): 170-178
58 Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of
nonalcoholic fatty liver disease demonstrates an exponential increase in burden of
disease: Estes et al. Hepatology. 2018 Jan;67(1):123–33.
59 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global
69
epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of
prevalence, incidence, and outcomes. Hepatology. 2016 Jul;64(1):73–84.
60 Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S.
Nonalcoholic Steatohepatitis: A Review. JAMA. 2020 Mar;323(12):1175.
61 Fang Y-L, Chen H, Wang C-L, Liang L. Pathogenesis of non-alcoholic fatty liver
disease in children and adolescence: From “two hit theory” to “multiple hit model.”
WJG. 2018 Jul;24(27):2974–83.
62 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic
fatty liver disease (NAFLD). Metabolism. 2016 Aug;65(8):1038–48.
63 Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al.
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated
Fatty Liver Disease. Gastroenterology. 2020 May;158(7):1999-2014.e1.
64 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver
Disease. Int J Mol Sci. 2020 Aug;21(16):E5888.
65 Chaney A. Obesity and Nonalcoholic Fatty Liver Disease. Nurs Clin North Am. 2021
Dec;56(4):543–52.
66 Luo Y, Lin H. Inflammation initiates a vicious cycle between obesity and
nonalcoholic fatty liver disease. Immun Inflamm Dis. 2021 Mar;9(1):59–73.
67 Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global
epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic
70
review and meta-analysis. Journal of Hepatology. 2019 Oct;71(4):793–801.
68 Xu Y, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease
and coronavirus disease 2019: clinical relationship and current management. Lipids
Health Dis. 2021 Dec;20(1):126.
69 Lee WM, Bae JH, Chang Y, Lee SH, Moon JE, Jeong SW, et al. Effect of Nutrition
Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia
Pharmacotherapy: A Randomized Controlled Trial. Nutrients. 2021 Dec;13(12):4453.
70 Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. Journal of
Hepatology. 2020 Apr;72(4):785–801.
71 Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical Models
for Studying NASH-Driven HCC: How Useful Are They? Cell Metabolism. 2019
Jan;29(1):18–26.
72 Horn CL, Morales AL, Savard C, Farrell GC, Ioannou GN. Role of CholesterolAssociated Steatohepatitis in the Development of NASH. Hepatol Commun.
2021;6(1)12–35.
73 Duparc T, Briand F, Trenteseaux C, Merian J, Combes G, Najib S, et al. Liraglutide
improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse
model of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2019
Oct;317(4):G508–17.
74 Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, et al. A 3week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic
71
inflammation and cell death. Clin Transl Sci. 2020 May;13(3):529–38.
75 Gould S, Scott RC. 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology
review. Food and Chemical Toxicology. 2005 Oct;43(10):1451–9.
76 Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, et al. Bile
acids induce energy expenditure by promoting intracellular thyroid hormone
activation. Nature. 2006 Jan;439(7075):484–9.
77 Murphy C, Parini P, Wang J, Björkhem I, Eggertsen G, Gåfvels M. Cholic acid as key
regulator of cholesterol synthesis, intestinal absorption and hepatic storage in mice.
Biochim Biophys Acta. 2005 Aug;1735(3):167–75.
78 Vergnes L, Phan J, Strauss M, Tafuri S, Reue K. Cholesterol and cholate components
of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression.
J Biol Chem. 2003 Oct;278(44):42774–84.
79 Jamshed H, Arslan J, Gilani A-H. Cholesterol-cholate-butterfat diet offers multiorgan dysfunction in rats. Lipids Health Dis. 2014 Dec;13:194.
80 Williams III RO, Mahaguna V, Sriwongjanya M. Characterization of an inclusion
complex of cholesterol and hydroxypropyl-β-cyclodextrin. European Journal of
Pharmaceutics and Biopharmaceutics. 1998 Nov;46(3):355–60.
81 Li T, Matozel M, Boehme S, Kong B, Nilsson L-M, Guo G, et al. Overexpression of
cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and
maintains cholesterol homeostasis. Hepatology. 2011 Mar;53(3):996–1006.
72
82 Lambert G, Amar MJA, Guo G, Brewer HB, Gonzalez FJ, Sinal CJ. The farnesoid Xreceptor is an essential regulator of cholesterol homeostasis. J Biol Chem. 2003
Jan;278(4):2563–70.
83 Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, et al. A
farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue
metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic
stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther. 2005
Aug;314(2):584–95.
84 Ichimura M, Masuzumi M, Kawase M, Sakaki M, Tamaru S, Nagata Y, et al. A dietinduced Sprague–Dawley rat model of nonalcoholic steatohepatitis-related cirrhosis.
The Journal of Nutritional Biochemistry. 2017 Feb;40:62–9.
85 Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et
al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
N Engl J Med. 2021 Oct;385(17):1559–69.
86 Fang JG, Zhu J, Li XJ, Li R, Dai F, Song XM, et al. [Epidemiological survey of
prevalence of fatty liver and its risk factors in a general adult population of Shanghai].
Zhonghua Gan Zang Bing Za Zhi. 2005 Feb;13(2):83–8.
87 Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk
factor of nonalcoholic fatty liver disease in premenopausal women. World J
Gastroenterol. 2012 Jan;18(3):237–43.
88 Palmisano BT, Zhu L, Stafford JM. Role of Estrogens in the Regulation of Liver Lipid
73
Metabolism. Adv Exp Med Biol. 2017;1043:227–56.
89 Meda C, Barone M, Mitro N, Lolli F, Pedretti S, Caruso D, et al. Hepatic ERα
accounts for sex differences in the ability to cope with an excess of dietary lipids. Mol
Metab. 2020 Feb;32:97–108.
90 Zhang B, Zhang C-G, Ji L-H, Zhao G, Wu Z-Y. Estrogen receptor β selective agonist
ameliorates liver cirrhosis in rats by inhibiting the activation and proliferation of
hepatic stellate cells. J Gastroenterol Hepatol. 2018 Mar;33(3):747–55.
91 Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, et al. Prevalence and risk
factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol
Hepatol. 2006 Jan;21(1 Pt 1):138–43.
92 Balakrishnan M, Patel P, Dunn-Valadez S, Dao C, Khan V, Ali H, et al. Women Have
a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression
vs Men: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021
Jan;19(1):61-71.e15.
93 Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, et al.
Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver
disease (NAFLD): a cross-sectional study. J Hepatol. 2008 Feb;48(2):300–7.
94 Mokhtari Z, Poustchi H, Eslamparast T, Hekmatdoost A. Egg consumption and risk
of non-alcoholic fatty liver disease. World J Hepatol. 2017 Apr;9(10):503–9.
95 Noureddin M, Zelber-Sagi S, Wilkens LR, Porcel J, Boushey CJ, Le Marchand L, et
al. Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse
74
Population: The Multiethnic Cohort. Hepatology. 2020 Jun;71(6):1940–52.
96 Yasutake K, Nakamuta M, Shima Y, Ohyama A, Masuda K, Haruta N, et al.
Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease:
the significance of dietary cholesterol. Scand J Gastroenterol. 2009;44(4):471–7.
97 Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS. Switch-like control of
SREBP-2 transport triggered by small changes in ER cholesterol: a delicate balance.
Cell Metab. 2008 Dec;8(6):512–21.
98 Yang Z-X, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver
lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int. 2010
Aug;4(4):741–8.
99 Yu L, Gupta S, Xu F, Liverman ADB, Moschetta A, Mangelsdorf DJ, et al. Expression
of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J
Biol Chem. 2005 Mar;280(10):8742–7.
100
Santhekadur PK, Kumar DP, Sanyal AJ. Preclinical models of non-alcoholic
fatty liver disease. J Hepatol. 2018 Feb;68(2):230–7.
75
...
論文の公開元へ
